3 Stocks That Could Attract Attention: Burning Rock Biotech (BNR), Cardiol Therapeutics (CRDL), DBV Technologies (DBVT)

Healthcare and biotechnology stocks remain active areas of interest as companies push forward with late-stage development programs and precision-focused treatment strategies. Investors continue monitoring clinical progress, financial positioning, and pipeline advancements as key indicators of future value creation across the sector.

Burning Rock Biotech Ltd ADR (BNR)

Burning Rock Biotech Ltd ADR (NASDAQ: BNR) flaunted a decline of -11.09% at $14.51, as the Stock market plummeted on May 22, 2026. During the day, the stock rose to $16.12 and sank to $14.51. Taking a long-term approach, BNR posted a 52-week range of $2.80-$41.72.

The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 40.80%. Meanwhile, its Annual Earnings per share during the time was 40.80%.  This publicly-traded company’s shares outstanding now amount to $8.79 million, simultaneously with a float of $8.77 million. The organization now has a market capitalization of $127.54 million.

Cardiol Therapeutics Inc. (CRDL)

Cardiol Therapeutics Inc. (NASDAQ: CRDL) is continuing to broaden its cardiovascular pipeline by targeting inflammatory conditions that currently lack effective disease-specific therapies. As the role of inflammation in cardiac disease becomes increasingly recognized, companies developing therapies focused on underlying disease mechanisms are drawing growing attention from investors and clinicians alike.

Market Momentum

As of May 22, 2026, CRDL closed at $1.32, up 0.76%, with trading volume of 281,359 shares versus an average volume of 694,533 shares. The company currently carries a market capitalization of $152.159M and a beta of 0.43, reflecting relatively controlled volatility compared to many clinical-stage biotech peers. Shares continue trading within their 52-week range of $0.8800 to $1.71, while the 1-year target estimate of $7.32 indicates meaningful upside potential tied to future clinical advancement.

Clinical Expansion: Acute Myocarditis

Cardiol’s Phase II ARCHER study evaluated CardiolRx™ in acute myocarditis, an inflammatory condition affecting the heart muscle that can lead to arrhythmias, impaired cardiac function, and heart failure. Clinical findings demonstrated reductions in cardiac inflammation along with structural improvements, including decreases in left ventricular mass, an important indicator associated with cardiac remodeling and recovery.

Addressing Unmet Need

Current treatment approaches for myocarditis remain largely supportive, with limited therapies directly targeting inflammatory disease progression. Cardiol’s strategy of addressing the inflammatory drivers of cardiac injury may provide a differentiated therapeutic approach for patients who currently face few targeted treatment alternatives.

Outlook

As Cardiol continues building clinical evidence across multiple inflammatory cardiovascular conditions, successful advancement in myocarditis could significantly expand the company’s long-term commercial opportunity while strengthening the broader value of its development platform.

DBV Technologies ADR (DBVT)

Witnessing the stock’s movement on the chart, on May 22, 2026, DBV Technologies ADR (NASDAQ: DBVT) had a quiet start as it plunged -2.10% to $18.18. During the day, the stock rose to $18.80 and sank to $18.03. Taking a long-term approach, DBVT posted a 52-week range of $7.53-$26.18.

The Healthcare sector firm’s twelve-monthly sales growth has been 18.68% for the last half of the decade. Meanwhile, its Annual Earnings per share during the time was 18.68%.  Nevertheless, the stock’s Earnings Per Share (EPS) this year is 4.36%. This publicly-traded company’s shares outstanding now amount to $59.18 million, simultaneously with a float of $48.10 million. The organization now has a market capitalization of $1.01 billion.